| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000038045 |
| Receipt No. | R000043367 |
| Scientific Title | Effects of lactic acid bacteria intake on perimenopausal women on menopause-like symptoms, sleep and biomarkers |
| Date of disclosure of the study information | 2020/12/19 |
| Last modified on | 2019/12/26 (Ver. 4) |
| Basic information | ||
| Public title | Effects of lactic acid bacteria intake on perimenopausal women on menopause-like symptoms, sleep and biomarkers | |
| Acronym | Effects of lactic acid bacteria intake on perimenopausal women on menopause-like symptoms, sleep and biomarkers | |
| Scientific Title | Effects of lactic acid bacteria intake on perimenopausal women on menopause-like symptoms, sleep and biomarkers | |
| Scientific Title:Acronym | Effects of lactic acid bacteria intake on perimenopausal women on menopause-like symptoms, sleep and biomarkers | |
| Region |
|
|
| Condition | ||
| Condition | Healthy adult | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | YES | |
| Objectives | |
| Narrative objectives1 | To investigate the effects of lactic acid bacteria on menopause-like symptoms, sleep and biomarkers after 8 weeks of ingestion. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | Kupperman Kohnenki Shogai Index (KKSI) at 8 weeks ingestion |
| Key secondary outcomes | 1. Swelling
2. Blood flow 3. Stiff shoulder VAS 4. QOL questionnaire (SF-36) 5. Pittsburgh Sleep Quality Index (PSQI-j) 6. OSA sleep inventory MA version 7. Heart rate / activity survey |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Ingestion of test food anytime except before going to bed. Or ingestion of test food before going to bed. | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Female | |||
| Key inclusion criteria | (1) Female older than 45 years and younger than 55 years
(2) Subjects who are aware of aging irregular menstruation, indefinite complaints and poor sleep (3) Subjects who can appropriately conduct heart rate and activity surveys (4) Subjects judged to be healthy by a doctor |
|||
| Key exclusion criteria | (1) Subjects who can not properly collect hair, saliva and blood flow test
(2) Subjects with history, treatment history, medication, or health food intake affecting the assessment of climacteric symptoms (3) Subjects with history, treatment history, medication, or health food consumption that affect sleep assessment (4) Subjects who have passed more than one year after menopause (5) Subjects who take excessive amounts of soybean products such as natto and soy beverages (6) Subjects who take foods rich in lactic acid bacteria (yogurt, lactic acid bacteria beverages, etc.) at least three times a week (7) Subjects who have undergone oophorectomy or hysterectomy (8) Excessive smokers, alcohol addicts, and subjects with extremely irregular diets (9) Subjects whose overall score of the Pittsburgh Sleep Questionnaire at the pre-examination is less than 3, or more than 10, or who are estimated to have sleep disorders such as insomnia from the answers (10) Subjects whose BMI are 30.0 kg/m^2 or more (11) Subjects who are awakened midway through external factors such as child crying at least twice a week (12) Night and day shift worker or manual laborer (13) Subjects who have under treatment or a history of serious disease (e.g., diabetes, liver disease, kidney disease, or heart disease) and disease to affect the adrenal cortical hormone secretion (14) Subjects who are judged as unsuitable for the study based on the results of lifestyle questionnaire (15) Subjects who are judged as unsuitable for the study because of clinical test, anthropometric test and physical examination in pre-inspection (16) Subjects who have participated in other clinical study within the last one month or have plan to participate other clinical studies (17) Subjects who are pregnant or lactating, or plan to become pregnant or lactate during the study (18) Subjects who are judged as unsuitable for the study by investigator for other reasons |
|||
| Target sample size | 10 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | NISSIN FOODS HOLDINGS CO., LTD.
R&D Platform NISSIN Global Innovation Center |
||||||
| Division name | Health Science Research Office | ||||||
| Zip code | 192-0001 | ||||||
| Address | 2100, Tobukimachi, Hachioji, Tokyo | ||||||
| TEL | 042-696-7685 | ||||||
| soichi.tanabe@nissin.com | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | TTC Co., Ltd. | ||||||
| Division name | Clinical Research Planning Department | ||||||
| Zip code | 150-0021 | ||||||
| Address | Seibu Shinkin Bank Ebisu Bldg.,1-20-2, Ebisunishi, Shibuya-ku, Tokyo | ||||||
| TEL | 03-5459-5329 | ||||||
| Homepage URL | |||||||
| s.tsuji@ttc-tokyo.co.jp | |||||||
| Sponsor | |
| Institute | TTC Co., Ltd. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | NISSIN FOODS HOLDINGS CO., LTD. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Aisei Hospital Ueno Clinic Research Ethics Committee |
| Address | 2-18-6, Higashiueno, Taitou-ku, Tokyo |
| Tel | 03-6455-0880 |
| t.saito@ttc-smo.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043367 |